Evaluating Summit Therapeutics – Look Beyond Technicals to Assess Fundamentals

By Susan Ramirez • Friday, December 06 10:17 • Permanent Link

Summit Therapeutics logged a 5.8% change during today's morning session, and is now trading at a price of $18.54 per share. The S&P 500 index moved 0.0%. SMMT's trading volume is 695,101 compared to the stock's average volume of 5,227,341.

If you are considering an investment in SMMT, you'll want to know the following:

Summit Therapeutics has moved 700.0% over the last year, and the S&P 500 logged a change of 31.9%
Based on its trailing earnings per share of -0.23, Summit Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -80.6 while the S&P 500 average is 29.3
SMMT has a forward P/E ratio of -48.8 based on its forward 12 month price to earnings (EPS) of $-0.38 per share
Its Price to Book (P/B) ratio is 31.21 compared to its sector average of 3.53
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.
Based in Miami, the company has 105 full time employees and a market cap of $13.67 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.